Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.
The phase 3 study found the combination effective, regardless of tumor proportion score.
Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).
PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.
Early trial results show that immunotherapy using chimeric antigen receptor (CAR) T-cell therapy may be effective in patients with multiple myeloma.
Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.
Because of the drug's promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.
The firefighting profession has previously been associated with a higher risk of MGUS and myeloma compared with the general population.
A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.
A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
In the future, targets of drug development may be within the microbiome.
KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Noninvasive Exhaled Breath Test May Be Effective In Diagnosing Esophagogastric Cancers
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Pediatric CML: Life-Long Considerations With TKI Therapy
- Bladder Cancer, UTUC More Common in Kidney Transplant Recipients